"One-shot" vaccination available in Foshan
Foshan China 2021-06-10 11:59

  On June 8th, the highly anticipated "one-shot" vaccine was distributed to citizens in Shunde District and Sanshui District, Foshan. How was the first day of injection? Lets take a look.


  Longjiang Anti-virus Staff Activity Center (龙江防保职工活动中心) was one of the sites for the new vaccine. On June 8th, adenovirus vaccine (Ad5-nCoV), also known as "one-shot" vaccine, was given to local residents, with a total of 3,500 doses on the first day.


  "Today, we serve one-shot vaccine. Citizens who have been vaccinated with other types of vaccines shall not apply." At 1:30 p.m., people started to line up orderly as volunteers and medical staff kept reminding that the "one-shot” vaccine belongs to a different category from vaccines produced by Beijing Kexing and Beijing Biology, which were categorized as "inactivated vaccines". People cannot mix them up when getting vaccinated.

  Reportedly, Ad5-nCoV came as a joint effort from the team of Academician Chen Wei at Medical Research Institute, Academy of Military Medical Sciences and CanSino Biologics Inc, which was approved to land on the Chinese market by National Medical Products Administration (NMPA) in February 2021.


  According to Zhang Xuecui, Deputy Director of Prevention and Protection Section of Longjiang Community Health Service Center, after being vaccinated with "one-shot" vaccine, citizens might show similar responses to other types of vaccines, including redness, swelling, heat, and pain in the injection spot. "Drink enough amount of water. Get some rest. These symptoms will fade away."

  As another vaccination to protect people from COVID-19, what are  the differences and commonalities between "one-shot" vaccine and inactivated vaccines?

  Different vaccination procedures

  To get basic immunization, adenovirus vaccine requires 1 dose (0.5ml), while inactivated vaccine requires 2 doses (0.5ml each) with a recommended interval of 3 to 8 weeks.


  Based on data from Phase III Clinical Trial, 28 days after vaccination, recipients can gain a total protective efficacy of 65.28% against all COVID-19 symptoms and 90.07% against severe symptoms. Plus, from the most recent resetal illness or family history

  3) those with a history of asthma

  4) patients with tharch, the vaccine also has a protective effect on mutant strain.

  Same degree of safety

  Adenovirus vaccine holds some commonalities with the three previous inactivated vaccines, including vaccination method (injected at deltoid muscle of the upper arm), age range (18-59), and security. 


  Contraindications for adenovirus vaccine are similar to those of the other three inactivated vaccines, but the following group of people should use with caution:

  1) those with HIV infection, scleroderma, dermatomyositis, and lupus erythematosus and other autoimmune diseases are not recommended at this point

  2) those diagnosed with diabetes and a history of convulsions, epilepsy, encephalopathy, menrombocytopenia and any coagulopathy (for intramuscular injection of this product may cause bleeding)

  As noted, recipients should choose the same product to complete the vaccination. For those who have received one dose of inactivated vaccine, they should continue to use inactivated vaccine. For those who have already received 2 doses of inactivated vaccine, they are not recommended to take adenovirus vaccine to improve protection efficacy.


  Author | Jersey

  Revisor | Jessica

  Photo & Video | 顺德疾控, Zhujiang Business, Foshan News Network